Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients aged ≥18 years at index date.
Patients with PsO diagnosed with PsA (concomitant or sequentially), either by a rheumatologist or dermatologist, at least 6 months prior to initiation of secukinumab treatment.
Continuously treated with secukinumab for at least 24 weeks (6 months) after index date.
Medical history available from at least the one-year study period (at least 6 months previous to the start of secukinumab treatment and at least 6 months after).
You may not be if
Patients who interrupted secukinumab treatment for 3 or more months during the 6-month period (post-period) for any cause.
Patients known to be participating in an interventional study at any point of the one-year study period.
Clareo Health | Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment
